Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDNovo Nordisk A/S Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 1 | $6.31 | $6.50 | $6.45 |
| Q2 2025 | 1 | $6.48 | $6.68 | $6.62 |
| Q3 2025 | 1 | $7.37 | $7.59 | $7.53 |
| Q4 2025 | 1 | $7.39 | $7.61 | $7.55 |
| Q1 2026 | 1 | $6.87 | $7.08 | $7.02 |
| Q2 2026 | 1 | $7.68 | $7.90 | $7.84 |
| Q3 2026 | 1 | $8.35 | $8.60 | $8.53 |
| Q4 2026 | 1 | $8.19 | $8.44 | $8.37 |
Novo Nordisk A/S Earnings Date And Information
Novo Nordisk A/S last posted its earnings results on Wednesday, February 5th, 2025. The company reported $0.91 earnings per share for the quarter, topping analysts' consensus estimates of $0.88 by $0.03. The company had revenue of 85.68 B for the quarter and had revenue of 290.40 B for the year. Novo Nordisk A/S has generated $23 earnings per share over the last year ($22.64 diluted earnings per share) and currently has a price-to-earnings ratio of 22.39. Novo Nordisk A/S has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based on prior year's report dates.
Novo Nordisk A/S Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 02/05/2025 | Q4 2024 | $0.88 | $6.34 | 5.46 | $80.21 B | $85.68 B |
| 09/28/2024 | Q3 2024 | N/A | $6.13 | N/A | $71.85 B | $71.31 B |
| 06/29/2024 | Q2 2024 | N/A | $4.50 | N/A | $69.28 B | $68.06 B |
| 03/30/2024 | Q1 2024 | N/A | $5.70 | N/A | $63.38 B | $65.35 B |
| 12/30/2023 | Q4 2023 | N/A | $4.92 | N/A | $62.03 B | $65.86 B |
| 09/29/2023 | Q3 2023 | N/A | $5.02 | N/A | $57.80 B | $58.73 B |
| 06/29/2023 | Q2 2023 | N/A | $8.65 | N/A | $56.03 B | $54.30 B |
| 03/30/2023 | Q1 2023 | N/A | $8.81 | N/A | $52.46 B | $53.37 B |
| 12/30/2022 | Q4 2022 | N/A | $6.01 | N/A | N/A | $48.09 B |
| 09/29/2022 | Q3 2022 | N/A | $3.17 | N/A | $44.89 B | $45.57 B |
| 06/29/2022 | Q2 2022 | N/A | $2.93 | N/A | $40.76 B | $41.27 B |
| 03/30/2022 | Q1 2022 | N/A | $3.11 | N/A | N/A | $42.03 B |
| 12/30/2021 | Q4 2021 | N/A | $4.75 | N/A | N/A | $38.33 B |
| 09/29/2021 | Q3 2021 | N/A | $5.29 | N/A | $34.56 B | $35.62 B |
| 06/29/2021 | Q2 2021 | N/A | $5.26 | N/A | $32.35 B | $33.04 B |
| 03/30/2021 | Q1 2021 | N/A | $5.47 | N/A | N/A | $33.80 B |
| 12/30/2020 | Q4 2020 | N/A | $4.00 | N/A | N/A | $32.14 B |
| 09/29/2020 | Q3 2020 | N/A | $4.42 | N/A | $30.93 B | $30.93 B |
| 06/29/2020 | Q2 2020 | N/A | $4.54 | N/A | $31.52 B | $30.01 B |
| 03/30/2020 | Q1 2020 | N/A | $5.07 | N/A | N/A | $33.88 B |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Novo Nordisk A/S Earnings: FAQ's
Novo Nordisk A/S has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, February 5th, 2025 based offlast year's report dates.
In the previous quarter, Novo Nordisk A/S (:NVO) reported $0.91 earnings per share (EPS) to beat the analysts' consensus estimate of $0.88 by $0.03.
The conference call for Novo Nordisk A/S's latest earnings report can be listened to online.
The conference call transcript for Novo Nordisk A/S's latest earnings report can be read online.
Novo Nordisk A/S (:NVO) has a recorded annual revenue of $290.40 B.
Novo Nordisk A/S (:NVO) has a recorded net income of $100.99 B.Novo Nordisk A/S has generated $22.68 earnings per share over the last four quarters.
Novo Nordisk A/S (:NVO) has a price-to-earnings ratio of 22.39 and price/earnings-to-growth ratio is 3.35.